التفاصيل البيبلوغرافية
| العنوان: |
Invasive pneumococcal disease surveillance in Canada, 2021–2022. |
| المؤلفون: |
Griffith, Averil, Golden, Alyssa R., Lefebvre, Brigitte, McGeer, Allison, Tyrrell, Gregory J., Zhanel, George G., Kus, Julianne V., Hoang, Linda, Minion, Jessica, Van Caeseele, Paul, Smadi, Hanan, Haldane, David, Yang Yu, Xiaofeng Ding, Steven, Laura, McFadzen, Jan, Franklin, Kristyn, Martin, Irene |
| المصدر: |
Canada Communicable Disease Report; May2024, Vol. 50 Issue 5, p121-134, 14p |
| مصطلحات موضوعية: |
WHOLE genome sequencing, DRUG resistance in microorganisms, STREPTOCOCCUS pneumoniae, ERYTHROMYCIN, SEROTYPES, PNEUMOCOCCAL meningitis |
| مصطلحات جغرافية: |
CANADA, WINNIPEG (Man.) |
| الشركة/الكيان: |
UNIVERSITY of Manitoba |
| مستخلص: |
Background: Invasive pneumococcal disease (IPD, Streptococcus pneumoniae) has been a nationally notifiable disease in Canada since 2000. The use of conjugate vaccines has caused a shift in the distribution of serotypes over time. This report is a summary of the demographics, serotypes and antimicrobial resistance of IPD isolates collected in Canada in 2021 and 2022. Methods: The National Microbiology Laboratory (NML) of the Public Health Agency of Canada in Winnipeg, Manitoba collaborates with provincial and territorial public health laboratories to conduct national surveillance of IPD. There were 1,999 isolates reported in 2021 and 3,775 isolates in 2022. Serotype was determined by the Quellung reaction or whole-genome sequencing (WGS). Antimicrobial susceptibilities were determined by WGS methods, broth microdilution, or data shared by collaborators in the Canadian Antimicrobial Resistance Alliance program at the University of Manitoba. Population-based IPD incidence rates were obtained through the Canadian Notifiable Disease Surveillance System. Results: The incidence of IPD in Canada was 5.62 cases per 100,000 population in 2021, decreasing from the peak of 10.86 cases per 100,000 population in 2018. Serotypes with increasing trends (p<0.05) between 2018 and 2022 included: 4 (6.1%–12.4%), 9V (1.0%–5.1%) and 12F (4.8%–5.4%). The overall prevalence of PCV13 serotypes increased over the same period (31.2%−41.5%, p<0.05) while the prevalence of non-vaccine types decreased significantly (27.3%–21.5%, p<0.0001). The highest rates of antimicrobial resistance in 2021 and 2022 were seen with clarithromycin (21%, 2021; 24%, 2022) and erythromycin (22%, 2021; 24%, 2022). Multidrug-resistant IPD continued to increase from 2018 to 2022 (6.7%–12.6%, p<0.05). Conclusion: The number of cases of IPD continued to decrease in 2021 in comparison to previous years, however, 2022 saw a return to pre-COVID-19 levels. Disease due to PCV13 serotypes 3, 4, 9V and 19F, as well as non-PCV13 serotypes 12F and 20, is increasing in prevalence. Surveillance of IPD to monitor changing serotype distribution and antimicrobial resistance is essential. [ABSTRACT FROM AUTHOR] |
|
Copyright of Canada Communicable Disease Report is the property of Public Health Agency of Canada and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder